Pfizer Licenses T1DM Immunotherapy From AnTolRx
AnTolRx, a privately held biotech company, announced Pfizer has exercised its option to license AnTolRx’s antigen-specific immunotherapy for T1DM. According to the press release, AnTolRx will receive an up-front payment and is eligible for milestone and royalty payments. The specific financial terms were not disclosed. Below, FENIX provides thoughts on the AnTolRx opportunity in the context of other T1DM immunotherapies in development.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.